We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.01%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $33.33 · 6 analysts
Stored first · Google News · Yahoo Finance (English)
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside Stocktwits
Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
Corvus Pharmaceuticals (CRVS) Proxy filing Summary Quartr
Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary Quartr
Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary Quartr
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights Benzinga España
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - simplywall.st
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.17 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 17. | Goldman Sachs | — | Initiate coverage | — → Buy | — | Goldman Sachs: Buy |
| 2026. 03. 14. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 01. 23. | Jefferies | — | Maintain | Buy → Buy | — | Jefferies: Buy |
| 2026. 01. 22. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 01. 21. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 01. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,875,000 | $22.14M | 0.04% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 539,869 | $7.9M | 0.01% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 143,598 | $1.11M | 0.00% | — | New position |